Nanosuspension Technologies for Delivery of Poorly Soluble Drugs

Table 2

Examples of marketed nanosuspensions produced by media milling technique.

Trade name	Drug	Indication	Dosage form	Company	Status
Rapamune	Sirolimus	Immunosuppressive	Oral suspension/tablet; 1-2 mg	Wyeth	Marketed in 2000
Tricor	Fenofibrate	Hypercholesterolemia	Oral tablet; 48–145 mg	Abbott	Marketed in 2004
Emend	Aprepitant	Antiemetics	Oral capsule; 80–125 mg	Merck	Marketed in 2003
Megace ES	Megestrol	Antianorexia, cachexia	Oral suspension; 125 mg/mL	Par Pharmaceuticals	Marketed in 2005